AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell eyes the US$1.6 billion nerve repair market with Remplir™ launch.
- New leadership to drive growth as FDA approval expected in early 2025.
- Expansion backed by A$35 million in funding to target global markets.
Orthocell (ASX:OCC) is setting the stage to introduce its groundbreaking nerve repair product, Remplir™, into the United States, with FDA approval anticipated by early 2025. This launch could mark a major milestone for the Australian-based company, positioning it within the expansive US$1.6 billion nerve repair market. Orthocell's strategic approach is designed to fast-track Remplir's presence in the US, potentially its largest market.
To lead these efforts, Orthocell has brought onboard John Walker and Phillip Edmondson, both of whom have extensive experience in the US nerve repair sector. Their roles will focus on spearheading sales and marketing efforts, which aim to establish Remplir as a leading solution within the specialized field of nerve repair. This addition of skilled leadership is a key move to support Orthocell’s ambitious market goals.
Remplir has already demonstrated success in Australia, with more than 150 surgeons actively using the product in clinical settings. The favorable reception in the Australian market underscores Remplir's potential to gain traction rapidly in the US, where demand for innovative nerve repair solutions remains high. Orthocell’s collaboration with US-based surgeons, Centers of Excellence, and prominent research institutions over the past two years has been instrumental in building readiness for the product’s anticipated launch.
Paul Anderson, CEO of Orthocell, highlighted the rigorous preparations taken to accelerate the product's adoption once FDA clearance is granted. Anderson emphasized that the company’s groundwork and collaborations have established a strong foundation for Remplir’s success, potentially paving the way for significant revenue growth in the coming years.
Orthocell is also financially well-positioned for this US launch, holding approximately A$35 million to support this endeavor. The company’s expansion strategy extends beyond the United States, with additional plans targeting regions such as Singapore, Southeast Asia, Canada, and Europe, making Orthocell’s ambitions globally oriented.
Orthocell’s final preparatory phase involves the top-line results from its US market authorization study, expected in Q4 2024. These results will support its 510(K) application, a crucial step in Orthocell’s FDA approval process and subsequent market entry.
With its innovative approach and solid financial backing, Orthocell aims to make a substantial impact on the nerve repair market, driven by Remplir’s potential to enhance patient outcomes in the US and beyond.
